Thirona, a Dutch AI medical image analysis company, has licensed a patent allowing it to develop an AI algorithm that helps identify abnormalities in CT lung scans, ensuring early detection of Cystic Fibrosis (CF). The company will use the license to integrate a quantitative method for the analysis of chest CT scans as well
With only approximately 70,000 known cases every year, CF is a rare genetic disorder. Current clinical methods to detect the disease are both time consuming and require extensive training. Thirona lets clinicians automatically detect and quantify lung disease, improve care, and enhance clinical decision-making
This is a competitive space. One of Thirona’s competitors, NuvoAir recently shared three key pulmonology related studies presented at the 2020 North American Cystic Fibrosis (CF) conference showing that patients with the respiratory disease can achieve good quality spirometry at home through their platform
“Artificial intelligence algorithms make medical image analysis easier, more accurate and more effective. But it is hard work,” said Dr Eva van Rikxoort, managing director of Thirona. Our algorithm quickly and accurately detects “bronchiectasis and mucous quantifications in very young patients with CF, making personalized treatment easier. We believe this will have a substantial impact for patients and are proud to be part of the process,” she added.
